Judith Pérez-Granado

Ms. Judith Pérez-Granado

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2025 in Cancer Letters
Verified
Journal Article
Closed access
MNMina Nikanjam
Mina Nikanjam
JPJudith Pérez-Granado
Judith Pérez-Granado
MGMark Gramling
Mark Gramling
BLBruno Larvol
Bruno Larvol
RKRazelle Kurzrock
Razelle Kurzrock

1 January 2019 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
JPJudith Pérez-Granado
Judith Pérez-Granado
JPjanet pinero
janet pinero
LFLaura I. Furlong
Laura I. Furlong
The clinical efficacy of therapeutic monoclonal antibodies for breast and colorectal cancer has greatly contributed to the improvement of patients’ outcomes by individualizing their treatments according to their genomic background. However, primary or acquired resistance to treatment reduces its efficacy. In this context, the identification of biomarkers predictive of drug response would support research and development of new alternative treatments. Biomarkers play a major role in the genomic revolution, supporting disease diagnosis and treatment decision-making. Currently, several molecular biomarkers of treatment response for breast and colorectal cancer have been described. However, information on these biomarkers is scattered across several resources, and needs to be identified, collected and properly integrated to be fully exploited to inform monitoring of drug response in patients. Therefore, there is a need of resources that offer biomarker data in a harmonized manner to the user to support the identification of actionable biomarkers of response to treatment in cancer. ResMarkerDB was developed as a comprehensive resource of biomarkers of drug response in colorectal and breast cancer. It integrates data of biomarkers of drug response from existing repositories, and new data extracted and curated from the literature (referred as ResCur). ResMarkerDB currently features 266 biomarkers of diverse nature. Twenty-five percent of these biomarkers are exclusive of ResMarkerDB. Furthermore, ResMarkerDB is one of the few resources offering non-coding DNA data in response to drug treatment. The database contains more than 500 biomarker-drug-tumour associations, covering more than 100 genes. ResMarkerDB provides a web interface to facilitate the exploration of the current knowledge of biomarkers of response in breast and colorectal cancer. It aims to enhance translational research efforts in identifying actionable biomarkers of drug response in cancer.

16 September 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
JTJuan L. Trincado
Juan L. Trincado
MRMarina Reixachs-Solé
Marina Reixachs-Solé
JPJudith Pérez-Granado
Judith Pérez-Granado
TFTim Fugmann
Tim Fugmann
FSFerran Sanz
Ferran Sanz
EEEduardo Eyras
Eduardo Eyras
Immunotherapies provide effective treatments for previously untreatable tumors and identifying tumor-specific epitopes can help elucidate the molecular determinants of therapy response. Here, we describe a pipeline, ISOTOPE (ISOform-guided prediction of epiTOPEs In Cancer), for the comprehensive identification of tumor-specific splicing-derived epitopes. Using RNA sequencing and mass spectrometry for MHC-I associated proteins, ISOTOPE identified neoepitopes from tumor-specific splicing events that are potentially presented by MHC-I complexes. Analysis of multiple samples indicates that splicing alterations may affect the production of self-epitopes and generate more candidate neoepitopes than somatic mutations. Although there was no difference in the number of splicing-derived neoepitopes between responders and non-responders to immune therapy, higher MHC-I binding affinity was associated with a positive response. Our analyses highlight the diversity of the immunogenic impacts of tumor-specific splicing alterations and the importance of studying splicing alterations to fully characterize tumors in the context of immunotherapies. ISOTOPE is available athttps://github.com/comprna/ISOTOPE.

15 July 2022 in Genes
Verified
Journal Article
Open access
PDF file
JPJudith Pérez-Granado
Judith Pérez-Granado
JPjanet pinero
janet pinero
AMAlejandra Medina-Rivera
Alejandra Medina-Rivera
LFLaura I. Furlong
Laura I. Furlong
Understanding the molecular basis of major depression is critical for identifying new potential biomarkers and drug targets to alleviate its burden on society. Leveraging available GWAS data and functional genomic tools to assess regulatory variation could help explain the role of major depression-associated genetic variants in disease pathogenesis. We have conducted a fine-mapping analysis of genetic variants associated with major depression and applied a pipeline focused on gene expression regulation by using two complementary approaches: cis-eQTL colocalization analysis and alteration of transcription factor binding sites. The fine-mapping process uncovered putative causally associated variants whose proximal genes were linked with major depression pathophysiology. Four colocalizing genetic variants altered the expression of five genes, highlighting the role of SLC12A5 in neuronal chlorine homeostasis and MYRF in nervous system myelination and oligodendrocyte differentiation. The transcription factor binding analysis revealed the potential role of rs62259947 in modulating P4HTM expression by altering the YY1 binding site, altogether regulating hypoxia response. Overall, our pipeline could prioritize putative causal genetic variants in major depression. More importantly, it can be applied when only index genetic variants are available. Finally, the presented approach enabled the proposal of mechanistic hypotheses of these genetic variants and their role in disease pathogenesis.

30 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
MNMina Nikanjam
Mina Nikanjam
JPJudith Pérez-Granado
Judith Pérez-Granado
MGMark W. Gramling
Mark W. Gramling
BLBruno Larvol
Bruno Larvol
RKRazelle Kurzrock
Razelle Kurzrock
Claudin 18.2 (CLDN18.2) is exclusively expressed on gastric mucosal cell tight junctions with minimal expression in other healthy adult tissues. Prior studies assessed expression by immunohistochemistry, mainly membrane staining. The FDA CLDN18.2 threshold for zolbetuximab approval is ≥75% moderate to strong staining. Higher level expression has been seen in a number of cancers including (but not limited to) gastric, gastroesophageal junction (GEJ), pancreatic, and ovarian cancers. CLDN18.2 expression can change with treatment and can exhibit heterogeneity between tumor sites. Zolbetuximab is a recently FDA-approved anti-CLDN18.2 monoclonal antibody for first-line therapy of gastric/GEJ cancers in combination with chemotherapy based on the improvement in outcomes demonstrated in the biomarker selected populations of the SPOTLIGHT and GLOW trials. Given limited single-agent responses rates to zolbetuximab, a number of other CLDN18.2-directed therapies, including antibody-drug conjugates, CAR-T cells, and bispecific antibodies, are under exploration in clinical trials. Despite expression of CLDN18.2 on the gastric mucosa, these therapies have overall been tolerable in clinical trials, albeit with the use of aggressive anti-emetic regimens. Herein, we summarize CLDN18.2 expression in cancer along with clinical trials of zolbetuximab and other CLDN18.2-directed therapies. Given the variability in CLDN18.2 expression within and between tumor types, biomarker-driven approaches will be critical for patient selection in clinical trials and therapeutic approaches.

18 June 2020 in bioRxiv
Verified
Preprint
Open access
JTJuan L. Trincado
Juan L. Trincado
MRMarina Reixachs-Sole
Marina Reixachs-Sole
JPJudith Pérez-Granado
Judith Pérez-Granado
TFTim Fugmann
Tim Fugmann
FSFerran Sanz
Ferran Sanz
EEEduardo Eyras
Eduardo Eyras
Immunotherapies provide effective treatments for previously untreatable tumors and identifying tumor-specific epitopes can help elucidate the molecular determinants of therapy response. Here, we describe a pipeline, ISOTOPE (ISOform-guided prediction of epiTOPEs In Cancer), for the comprehensive identification of tumor-specific splicing-derived epitopes. Using RNA sequencing and mass spectrometry for MHC-I associated proteins, ISOTOPE identified neoepitopes from tumor-specific splicing events that are potentially presented by MHC-I complexes. Analysis of multiple samples indicates that splicing alterations may affect the production of self-epitopes and generate more candidate neoepitopes than somatic mutations. Although there was no difference in the number of splicing-derived neoepitopes between responders and non-responders to immune therapy, higher MHC-I binding affinity was associated with a positive response. Our analyses highlight the diversity of the immunogenic impacts of tumor-specific splicing alterations and the importance of studying splicing alterations to fully characterize tumors in the context of immunotherapies. ISOTOPE is available at https://github.com/comprna/ISOTOPE Author summary: Immune cells have the ability to attack tumor cells upon the identification of tumor-specific peptides, i.e., epitopes, that are presented by the major histocompatibility complex (MHC). New cancer immunotherapies that help trigger this process provide a promising therapeutic strategy. One crucial aspect for their success is the ability to determine the molecular properties of a tumor that are informative about the effectiveness of the therapy. Alterations in the way genes are processed to express RNA molecules could lead to the production of new peptides, with some of them potentially being presented as tumor epitopes and facilitate the attack of immune cells. It is therefore essential to facilitate the identification of these splicing-derived epitopes. In this work, we describe a computational pipeline that performs a comprehensive identification of splicing alterations in a tumor and the potential epitopes that they would produce. Analysis of tumor samples with our pipeline show that responders and non-responders to immune therapy do not show differences in the number of splicing-derived epitopes, but splicing neoepitopes have higher affinity to the MHC complex in responders. Our new pipeline facilitates the genome-scale analysis of the role of splicing alterations in shaping the molecular properties that influence response to immunotherapy.